Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use
Go back to Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use| StemCells, Inc. (NASDAQ: TEM) | Delayed: 48.61 +0.76 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.85 | 52 Week High | $0.45 | |||
| Open | $47.00 | 52 Week Low | $0.37 | |||
| Day High | $49.85 | P/E | N/A | |||
| Day Low | $46.68 | EPS | $-0.31 | |||
| Volume | 5,317,640 | |||||
